Tiragolumab 是一种与 T 细胞免疫球蛋白和 ITIM 结构域 (TIGIT) 结合的免疫检查点抑制剂。Tiragolumab 单独或与 PD-L1 抑制剂 Atezolizumab 联合使用,可能对多种实体恶性肿瘤有效,尤其是非小细胞肺癌。
生物活性 | Tiragolumab is an immune checkpoint inhibitor binding to T-cell immunoglobulin and ITIM domain (TIGIT). Tiragolumab, alone or in combination with thePD-L1inhibitor Atezolizumab, may be effective against multiple solid malignancies-most notably non-small cell lungcancer[1][2]. |
Clinical Trial | |
性状 | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |